Isatuximab

About This Treatment

Myeloma Clinical Trials



Trial of Isatuximab (SAR650984) in Patients With Intermediate and High Risk Smoldering Multiple Myeloma

This phase II trial studies how well isatuximab works in treating patients with high risk smoldering plasma cell myeloma. Immunotherapy with monoclonal antibodies, such as isatuximab, may induce changes in the body's immune system and may interfere with the ability of the tumor cells to grow and spread.

Learn more about this trial


Recently Updated

A Study to Evaluate the Safety and Pharmacokinetics of SAR650984 in Patients With Multiple Myeloma

The primary objective of this trial is to evaluate the safety of SAR650984 in patients with relapsed/refractory multiple myeloma (RRMM).

Learn more about this trial


Isatuximab in Combination With Cemiplimab in Relapsed/Refractory Multiple Myeloma (RRMM) Patients

The primary objective of this study is to evaluate the safety and tolerability of the combination of isatuximab (also known as SAR650984) and cemiplimab (also known as REGN2810) in patients with relapse/refractory multiple myeloma.

Learn more about this trial


Multinational Clinical Study Comparing Isatuximab, Carfilzomib And Dexamethasone To Carfilzomib And Dexamethasone In Relapse And/Or Refractory Multiple Myeloma Patients (IKEMA)

The primary objective of this study is to demonstrate the benefit of isatuximab in combination with carfilzomib and dexamethasone in the prolongation of Progression Free Survival (PFS) as compared to carfilzomib and dexamethasone in patients with relapsed and/or refractory multiple myeloma (MM) previously treated with 1 to 3 lines of therapy.

Learn more about this trial


Clinical Benefit of SAR650984, Bortezomib, Lenalidomide and Dexamethasone Combination in NDMM Patients Not Eligible for Transplant (IMROZ)

The primary objective of this study is to demonstrate the benefit of isatuximab (I) in combination with bortezomib (V), lenalidomide (R) and dexamethasone (d) in the prolongation of progression free survival (PFS) as compared with bortezomib, lenalidomide and dexamethasone in patients with newly diagnosed multiple myeloma (NDMM) not eligible for transplant.

Learn more about this trial

Treatment Information
Developed By

Sanofi

Treatment Classifications
Additional Names
  • SAR650984

Create Your Account

Create your account today and get matched to myeloma treatments and trials around the US.

  • Find treatments with eligible clinical trials.
  • Get a second opinion from a myeloma specialist.
  • Receive alerts when new treatments become available.
  • Our services are always free for patients and HIPAA compliant.

Create Account


Need Help?

(888) 828-2206

Weekdays 9am - 5pm EST

;